Once written off as a post-COVID biotech with unpredictable revenue, $ABCL is showing huge inflection: • Pipeline: ABCL635 in Phase 2, ABCL575 in Phase 1 • Deals: Secured $56M upfront from Jazz & $28M from Vertex • Runway: Strong cash cushion with ~$655M in liquidity Risks remain, but with deep liquidity, years of heavy CapEx are finally yielding clinical proof & commercial validation. High-conviction setup! Watching from the sidelines or building a position?
206 views
0 Comments
Join the conversation with 500,000+ other investors 💸
Create an account to get access to everything Blossom has to offer!
📊 Personalized algorithm based on your investing style, experience level and interests
📈 Powerful portfolio and dividend tracking tools
👀 See what top creators and others in the community are investing in
